Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as th...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2004-06, Vol.93 (12), p.1558-1560
Main Authors: Amit, Guy, Rosen, Amit, Wagshal, Avraham B., Bonneh, Dan Y., Liss, Tzvika, Grosbard, Aviva, Ilia, Reuven, Katz, Amos
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Anti-Arrhythmia Agents - therapeutic use
Atrial Fibrillation - drug therapy
Biological and medical sciences
Cardiac dysrhythmias
Cardiology. Vascular system
Cardiovascular disease
Cohort Studies
Comparative studies
Drug therapy
Drugs, Generic - therapeutic use
Emergency Service, Hospital - utilization
Female
Generic drugs
Heart
Humans
Male
Medical sciences
Patient Admission - statistics & numerical data
Propafenone - therapeutic use
Recurrence
Retrospective Studies
Therapeutic Equivalency
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2004.02.071